Global Achlorhydria Treatment Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Achlorhydria Treatment Market Segmentation, By Drugs (Metronidazole, Amoxicillin-clavulanate potassium, Ciprofloxacin and Rifaximin), Diagnosis (Intrinsic factor antibody test, Gastric biopsy, H. pylori test, Stomach acid test, Serum pepsinogen test, and Serum gastrin test), Symptoms (Abdominal bloating, Indigestion, Nausea, Acid reflux, Digestive issues, Diarrhea, Weak and brittle nails, Hair loss, and Undigested food in stools), Causes (Hypothyroidism, Antacids, Proton pump inhibitors, Weight loss surgeries, H. pylori infection, and Autoimmune disorders), End-Users (Clinics, Hospitals, Diagnostic centres, Home healthcare, others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2032

Achlorhydria Treatment Market Size

• The global achlorhydria treatment market size was valued at USD 50.50billion in 2024 and is expected to reach USD 76.33 billion by 2032, at a CAGR of 5.30% during the forecast period
• The market growth is largely fueled by the increasing prevalence of gastrointestinal disorders, growing awareness regarding digestive health, and the rising adoption of advanced diagnostic technologies for stomach acid-related conditions, leading to improved detection and treatment of Achlorhydria across clinical settings
• Furthermore, the growing geriatric population, higher incidence of autoimmune gastritis, and increasing use of medications such as proton pump inhibitors (PPIs) are driving the demand for effective Achlorhydria Treatment solutions. These converging factors are accelerating the uptake of innovative therapeutic options, thereby significantly boosting the industry's growth

Achlorhydria Treatment Market Analysis

• The Achlorhydria Treatment market is witnessing significant growth due to the increasing prevalence of gastrointestinal disorders, particularly among the aging population, and a rising number of patients suffering from chronic gastritis and autoimmune conditions that lead to reduced or absent stomach acid production
• The growing demand for effective therapeutic drugs and advanced diagnostic tools for early detection and management of achlorhydria is a major factor driving market expansion, along with the development of novel proton pump inhibitor alternatives and acid replacement therapies
• North America dominated the achlorhydria treatment market with the largest revenue share of 38.7% in 2024, driven by high healthcare expenditure, advanced diagnostic infrastructure, and increased awareness regarding digestive health. The U.S. leads the region due to a strong presence of key pharmaceutical players and continuous clinical research in gastric disorders
• Asia-Pacific is expected to be the fastest-growing region in the achlorhydria treatment market during the forecast period, owing to rising cases of malnutrition, increased healthcare access, and growing awareness regarding acid deficiency disorders, especially in countries like India, China, and Japan
• The Amoxicillin-clavulanate potassium segment dominated the largest market revenue share of 45.6% in 2024, driven by its broad-spectrum activity, established use in combination regimens targeting H. pylori and related gastric infections, and wide availability as both branded and generic formulations

Report Scope and Achlorhydria Treatment Market Segmentation     

Achlorhydria Treatment Market Trends

Enhanced Convenience Through AI and Precision Diagnostics

• A significant and accelerating trend in the global achlorhydria treatment market is the deepening integration of artificial intelligence (AI) and digital diagnostic tools in gastrointestinal disease management. This fusion of technologies is significantly enhancing clinical accuracy, patient monitoring, and personalized treatment outcomes

  • For instance, in March 2024, Mayo Clinic implemented AI-powered endoscopic imaging solutions to improve diagnostic precision in gastric acid deficiency conditions such as Achlorhydria. Similarly, GE HealthCare introduced advanced digital diagnostic platforms capable of identifying gastric abnormalities at an early stage, thereby improving patient outcomes

• AI integration in gastroenterology enables features such as predictive analytics to assess patient risk profiles and automated detection of mucosal changes through real-time imaging. For example, certain AI-enabled diagnostic systems can learn from patient data patterns to suggest optimized treatment pathways, providing more intelligent clinical alerts based on symptom progression. Furthermore, AI-assisted remote monitoring capabilities allow healthcare providers to track gastric pH levels or treatment adherence with improved accuracy, ensuring proactive intervention
• The seamless integration of AI with endoscopic and laboratory diagnostics facilitates centralized control over patient data and treatment management. Through a single digital interface, clinicians can monitor test results, prescribe proton pump inhibitors (PPIs), and adjust therapeutic regimens, creating a unified and data-driven clinical workflow
• This trend toward more intelligent, intuitive, and interconnected diagnostic systems is fundamentally reshaping expectations in gastrointestinal disease management. Consequently, companies such as Thermo Fisher Scientific and Abbott Laboratories are developing AI-driven diagnostic kits and molecular testing solutions capable of identifying gastric enzyme deficiencies with greater speed and precision
• The demand for AI-based diagnostic and treatment platforms is growing rapidly across both hospitals and specialty clinics, as healthcare providers increasingly prioritize early detection, efficient patient management, and personalized therapeutic approaches

Achlorhydria Treatment Market Dynamics

Driver

Growing Prevalence of Gastric Disorders and Advancements in Diagnostic Technologies

• The increasing prevalence of gastrointestinal disorders such as atrophic gastritis and gastric mucosal atrophy, coupled with advancements in diagnostic imaging and testing, is a major driver for the Achlorhydria Treatment market

  • For instance, in April 2024, Takeda Pharmaceuticals announced a clinical expansion of its acid-related disorder therapy portfolio aimed at addressing unmet medical needs in Achlorhydria and hypochlorhydria patients. Such strategic initiatives by leading pharmaceutical players are expected to drive the market growth during the forecast period

• As awareness of gastric health and the risks of chronic acid deficiency increases, patients and healthcare providers are emphasizing early diagnosis and effective management to prevent complications such as vitamin B12 deficiency and bacterial overgrowth
• Furthermore, the development of non-invasive diagnostic techniques such as urea breath tests, AI-assisted endoscopy, and serum gastrin analysis is expanding accessibility to accurate diagnosis, thereby supporting market expansion
• The growing focus on patient-centric care and precision medicine—along with the introduction of advanced proton pump inhibitors, H2 blockers, and enzyme replacement therapies—is propelling treatment adoption globally. In addition, rising healthcare expenditure and improved access to gastrointestinal specialists are enhancing the demand for Achlorhydria treatment solutions

Restraint/Challenge

Limited Awareness and High Diagnostic Costs

• Limited public and clinical awareness about Achlorhydria, coupled with the relatively high cost of diagnostic and therapeutic procedures, poses a significant restraint to market growth. In many developing regions, underdiagnosis remains prevalent due to a lack of specialized gastroenterology infrastructure

  • For instance, a 2023 study by the World Gastroenterology Organisation (WGO) revealed that over 45% of Achlorhydria cases in low-income countries remain undiagnosed due to insufficient access to diagnostic testing and healthcare awareness

• Addressing these gaps through nationwide awareness programs, clinician education, and the deployment of cost-effective diagnostic kits is essential to broaden patient reach. Companies such as Abbott and Bio-Rad Laboratories are investing in affordable pH testing and enzyme assay kits to overcome such barriers
• In addition, the relatively high treatment cost—particularly for patients requiring long-term supplementation and continuous monitoring—can be a challenge in price-sensitive markets. This economic constraint is further compounded by limited insurance coverage for rare gastric disorders
• Overcoming these challenges through increased funding for public health programs, expansion of insurance coverage, and innovation in low-cost diagnostic solutions will be crucial for sustaining the growth of the achlorhydria treatment market

Achlorhydria Treatment Market Scope

The market is segmented on the basis of drugs, diagnosis, symptoms, causes, end-users, and distribution channel

• By Drugs

On the basis of drugs, the Achlorhydria Treatment market is segmented into Metronidazole, Amoxicillin-clavulanate potassium, Ciprofloxacin and Rifaximin. The Amoxicillin-clavulanate potassium segment dominated the largest market revenue share of 45.6% in 2024, driven by its broad-spectrum activity, established use in combination regimens targeting H. pylori and related gastric infections, and wide availability as both branded and generic formulations. Clinicians frequently select amoxicillin-based combinations because they are well tolerated in pediatric and adult populations and fit into many guideline-recommended eradication protocols where acid suppression is altered. The drug’s strong supply chain presence across hospital and retail pharmacies ensures ready access in endemic and developed markets alike. Amoxicillin combinations are often included in empiric regimens where diagnostic certainty about acid status is delayed, which increases utilization. Public and private hospital formularies list amoxicillin-clavulanate as a core antibiotic for GI indications, driving institutional procurement. Its inclusion in national essential-medicine lists in several countries supports large-volume distribution and stable pricing. Reimbursement coverage for combination therapies further cements this drug’s revenue dominance. Ongoing educational programs for gastroenterologists and primary-care physicians emphasize early eradication of treatable infections, which reinforces amoxicillin demand. The combination’s role in reducing secondary complications associated with achlorhydria-linked dysbiosis continues to underpin its market leadership.

The Rifaximin segment is expected to register the fastest CAGR of 9.8% from 2025 to 2032, driven by growing recognition of gut microbiome modulation in achlorhydria management and the drug’s localized, low-absorption profile that reduces systemic adverse effects. Rifaximin’s efficacy in treating small intestinal bacterial overgrowth (SIBO) and related symptoms common in hypochlorhydric patients has broadened its clinical use beyond classic indications. Increasing clinician awareness of rifaximin’s role in symptom control—such as bloating and diarrhea linked to achlorhydria—has generated demand in outpatient and gastroenterology clinics. Manufacturers are developing branded rifaximin formulations and indication-specific dosing regimens that increase prescriber confidence. Health-system formularies are adding rifaximin for targeted SIBO protocols, which supports institutional uptake. The drug’s safety profile makes it attractive for longer or repeated courses in chronic hypochlorhydria-related dysbiosis. Emerging real-world studies and guideline mentions for microbiome-directed therapy further validate rifaximin’s utility and stimulate adoption. Growing patient preference for therapies that relieve functional GI symptoms without major systemic exposure also favors rifaximin. As awareness of microbiome-targeted treatment pathways rises, rifaximin is expected to outpace many legacy antibiotics in percentage growth.

• By Diagnosis

On the basis of diagnosis, the Achlorhydria Treatment market is segmented into Intrinsic factor antibody test, Gastric biopsy, H. pylori test, Stomach acid test, Serum pepsinogen test, and Serum gastrin test. The Intrinsic factor antibody test segment dominated the largest market revenue share of 39.4% in 2024, reflecting the prominence of autoimmune atrophic gastritis and pernicious anemia as well-recognized causes of achlorhydria that require specific serologic confirmation. Clinicians rely on intrinsic factor antibody testing to identify patients at risk of B12 deficiency and irreversible gastric atrophy, which drives downstream monitoring and treatment pathways. The test is widely available in hospital laboratories and specialty clinics, and its inclusion in diagnostic algorithms for unexplained anemia or malabsorption boosts utilization. Diagnostic panels for suspected autoimmune gastritis commonly include this assay, increasing per-patient testing values. Reimbursement coverage in many health systems for targeted autoimmune workups reinforces test uptake. The test’s role in risk stratification for gastric neoplasia surveillance further anchors its clinical importance. Specialist societies and guideline documents frequently reference intrinsic factor testing, increasing clinician ordering. As a result, this serologic assay accounts for a large portion of diagnostic spend related to achlorhydria evaluation.

The Serum gastrin test segment is projected to grow at the fastest CAGR of 10.2% from 2025 to 2032, driven by increased use of gastrin as a functional biomarker to detect hypo- or achlorhydric states and to differentiate causes such as atrophic gastritis from acid-suppressant effects. Rising clinician interest in objective biochemical markers for acid output has increased gastrin testing in dyspepsia and malabsorption workups. Point-of-care and faster turnaround platforms for gastrin measurement are making the test more accessible in outpatient settings. Growing awareness of hypergastrinemia as an indicator for gastric enterochromaffin cell changes and for informing surveillance strategies supports broader adoption. Research linking gastrin levels to microbiome shifts in achlorhydria patients has further stimulated diagnostic demand. Laboratories are expanding assay panels to include gastrin alongside pepsinogen and autoantibodies, increasing per-order revenue. As personalized management pathways for acid-related disorders advance, gastrin testing becomes a higher-value diagnostic, propelling its growth rate.

• By Symptoms

On the basis of symptoms, the Achlorhydria Treatment market is segmented into Abdominal bloating, Indigestion, Nausea, Acid reflux, Digestive issues, Diarrhea, Weak and brittle nails, Hair loss, and Undigested food in stools. The Indigestion segment dominated the largest market revenue share of 36.5% in 2024, because dyspepsia is the most common presenting complaint that triggers clinical evaluation for acid-related disorders and leads to broad diagnostic and therapeutic activity. Patients with persistent indigestion drive repeat visits, testing, and empiric treatments, creating recurring revenue streams for gastroenterology clinics and primary-care services. Indigestion prompts endoscopic referrals, H. pylori testing, and trial acid-suppression or alternative management, which increases utilization of both diagnostics and drugs. Public health campaigns and over-the-counter product use for dyspepsia also contribute to a high baseline market volume. Clinics offering holistic GI care bundle diagnostics and nutrition/therapy services, concentrating spend around indigestion pathways. The symptom’s prevalence across age groups amplifies cumulative market value relative to rarer manifestations. Education of general practitioners to screen indigestion more proactively has raised referral rates to specialty care, further increasing associated market transactions. Because indigestion often coexists with other GI complaints, bundled management increases per-patient commercial activity linked to achlorhydria evaluation.

The Undigested food in stools segment is expected to witness the fastest CAGR of 8.9% from 2025 to 2032, as growing clinical recognition of malabsorption and gastric hypochlorhydria as contributors to steatorrhea and visible undigested matter drives targeted diagnostic work-ups. Increased awareness among clinicians and patients about the link between low stomach acid and maldigestion has led to higher reporting rates and subsequent testing. Telehealth triage tools that capture stool-related symptoms are prompting more referrals for specialized GI assessment. Nutritionists and gastroenterologists are collaborating more closely to address malabsorption, generating demand for combined diagnostic and therapeutic services. As microbiome and SIBO testing become mainstream, clinicians increasingly investigate undigested stool complaints, boosting service volumes. Home stool collection kits and improved lab processing encourage patient engagement and repeat testing. This symptom’s direct impact on quality of life also motivates more aggressive clinical management, supporting faster growth of related market activity.

• By Causes

On the basis of causes, the Achlorhydria Treatment market is segmented into Hypothyroidism, Antacids, Proton pump inhibitors, Weight loss surgeries, H. pylori infection, and Autoimmune disorders. The Proton pump inhibitors (PPI) segment dominated the largest market revenue share of 44.7% in 2024, reflecting the widespread and often long-term use of PPIs which can induce hypochlorhydria and secondarily drive diagnostic and management activity for low acid states. High rates of PPI prescribing, sometimes without step-down strategies, have increased the clinical population presenting with drug-induced achlorhydria and acid-related dysbiosis. Efforts to manage PPI-associated complications — such as B12 monitoring, gastrin testing, and microbiome considerations — create additional diagnostic and therapeutic spend. Hospitals and outpatient clinics routinely review long-term PPI patients, generating ongoing service demand. Public debate and guideline updates around PPI deprescribing further stimulate clinical consultations and alternative therapy adoption. Because PPI exposure is common across primary care and gastroenterology settings, it underlies a large portion of achlorhydria-related case volume. Pharmaceutical stewardship programs attempting to optimize PPI use also add structured care activities that add to market transactions. The net effect is a concentration of market value around PPI-related achlorhydria management.

The Weight loss surgeries cause segment is expected to grow at the fastest CAGR of 11.0% from 2025 to 2032, as the global increase in bariatric procedures yields a larger cohort of patients at risk for post-operative achlorhydria and complex nutritional sequelae requiring long-term follow-up. Bariatric surgery alters gastric anatomy and acid production, which can precipitate hypochlorhydria and malabsorption syndromes necessitating diagnostics and supplemental therapies. Growth in elective metabolic surgery in emerging and developed markets is expanding the population needing specialized GI post-op surveillance. Multidisciplinary post-bariatric clinics that include gastroenterology, nutrition, and surgical follow-up generate recurring diagnostic and therapeutic revenue. Increased surgeon and patient awareness of acid-related long-term risks has driven protocols for routine testing and B12 monitoring, boosting market activity. Investments in post-operative care infrastructure and telemonitoring platforms also support faster uptake of achlorhydria-related services in this patient group. As bariatric volumes rise, the downstream demand for achlorhydria management services accelerates accordingly.

• By End-Users

On the basis of end-users, the Achlorhydria Treatment market is segmented into Clinics, Hospitals, Diagnostic centres, Home healthcare, and Others. The Hospitals segment dominated the largest market revenue share of 52.8% in 2024, driven by their role in providing comprehensive diagnostic workups (endoscopy, biopsy, advanced serology), inpatient management of severe complications, and administration of parenteral therapies and nutritional support for achlorhydric patients. Tertiary hospitals house the multidisciplinary teams—gastroenterology, hematology, nutrition, and surgery—required for complex case management, concentrating high-value diagnostics and interventions. Hospitals also act as referral centers for specialized testing such as gastric biopsies and advanced imaging, which increases institutional revenue. Many hospital systems run follow-up clinics for pernicious anemia and post-surgical complications, creating recurring service streams. Public and private hospital procurement channels and formularies centralize drug and device purchasing for achlorhydria care. Academic hospitals’ participation in clinical trials and registries adds research-related funding and service activity. The hospital setting therefore captures a large share of the market’s monetary value.

The Home healthcare segment is expected to register the fastest CAGR of 10.6% from 2025 to 2032, as aging populations, chronic care models, and caregiver preferences drive more achlorhydria management out of hospitals and into community or home settings. Growth in home delivery of parenteral nutrition, oral supplements, and remote monitoring of micronutrient status supports expanding home-care services. Telemedicine follow-ups and home phlebotomy services reduce clinic visits for stable patients but increase recurring service contracts and consumable distribution. Chronic B12 replacement programs and nutritional counseling are increasingly provided via home-health agencies, creating new revenue channels. Insurance and government programs that reimburse home infusion and home visit services further enable this shift. Improved logistics and remote patient education platforms increase caregiver confidence in home management, accelerating uptake. As healthcare systems prioritize cost-effective, decentralized care, home healthcare becomes a rapidly expanding end-user channel.

• By Distribution Channel

On the basis of distribution channel, the Achlorhydria Treatment market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. The Retail Pharmacy segment dominated the largest market revenue share of 47.2% in 2024, reflecting the large volume of outpatient prescriptions, over-the-counter symptomatic remedies, and ongoing refill demand for oral medications and supplements used in achlorhydria management. Community pharmacies are the primary access point for patients seeking both prescription and supportive products such as proton pump-stepdown aids, B12 supplements, and digestive enzyme adjuncts. Retail channels also capture sales of commonly used antibiotics and supportive GI products, driving consistent revenue. Consumer familiarity with neighborhood pharmacies and easy access for repeat prescriptions support high transaction volumes. Many retail pharmacies offer counseling and minor diagnostic services that guide therapy adherence, boosting per-patient spend. The widespread geographic footprint of retail outlets, especially in suburban and rural areas, further concentrates distribution value. Partnerships between retail chains and clinics for medication management programs increase channel importance.

The Online Pharmacy channel is projected to grow the fastest with a CAGR of 13.4% from 2025 to 2032, driven by increasing telehealth usage, subscription medication services, and caregiver demand for doorstep delivery of chronic therapeutics and nutritional supplements. Online platforms offer convenience for patients on lifelong regimens, automated refills, and discreet ordering for sensitive GI conditions. Integration with electronic prescriptions and specialty pharmacy services enables prompt delivery of both routine and temperature-sensitive products. As logistics networks and cold-chain capabilities improve, online pharmacies become viable for a wider range of achlorhydria products. Digital patient portals and adherence programs bundled with online dispensing encourage loyalty and recurring revenue. Regulatory acceptance of e-prescriptions in more jurisdictions also accelerates channel adoption. The combination of convenience, digital health integration, and expanding product availability positions online pharmacies to outpace traditional channels in growth rate.

Achlorhydria Treatment Market Regional Analysis

• North America dominated the achlorhydria treatment market with the largest revenue share of 38.7% in 2024, driven by high healthcare expenditure, advanced diagnostic infrastructure, and increasing awareness regarding digestive health. The presence of major pharmaceutical and diagnostic companies, along with strong investments in gastrointestinal research, has further accelerated market growth in the region
• The region’s healthcare systems have rapidly adopted advanced diagnostic technologies such as AI-based endoscopy and non-invasive gastric pH testing, ensuring accurate and early detection of Achlorhydria and related gastric conditions
• In addition, a growing geriatric population and lifestyle factors contributing to gastric atrophy are fueling treatment demand across both hospital and specialty clinic settings. Reimbursement policies and the availability of innovative therapies also continue to strengthen market adoption

U.S. Achlorhydria Treatment Market Insight

The U.S. achlorhydria treatment market captured the largest revenue share within North America in 2024, supported by high healthcare spending, a well-established network of gastroenterology specialists, and early adoption of precision medicine. The U.S. remains at the forefront of clinical research in gastric disorders, with pharmaceutical leaders such as Takeda, AbbVie, and AstraZeneca actively investing in acid-related therapy pipelines. Furthermore, strong awareness initiatives by organizations such as the American Gastroenterological Association (AGA) are enhancing early diagnosis and treatment accessibility. Growing emphasis on personalized treatment, coupled with robust insurance coverage and patient support programs, continues to position the U.S. as a dominant market player.

Europe Achlorhydria Treatment Market Insight

The Europe achlorhydria treatment market is projected to expand at a substantial CAGR during the forecast period, driven by advanced diagnostic infrastructure, growing awareness of digestive disorders, and increasing adoption of personalized healthcare. European nations are prioritizing early intervention strategies and the integration of AI-based endoscopic imaging tools for gastric assessment. The presence of leading research institutions and biopharmaceutical firms across Germany, the U.K., and France further supports innovation in Achlorhydria diagnosis and treatment. The region is also witnessing significant investments in clinical trials focused on enzyme replacement and gastric acid restoration therapies.

U.K. Achlorhydria Treatment Market Insight

The U.K. achlorhydria treatment market is anticipated to grow at a noteworthy CAGR during the forecast period, supported by the expansion of the National Health Service (NHS) programs promoting early gastrointestinal screening. Increasing prevalence of vitamin B12 deficiency and related gastric disorders is encouraging the uptake of diagnostic and therapeutic solutions. The country’s strong focus on precision diagnostics and medical technology innovation continues to drive market growth.

Germany Achlorhydria Treatment Market Insight

The Germany achlorhydria treatment market is expected to witness considerable expansion, driven by the nation’s strong emphasis on clinical research, healthcare quality, and patient safety. Germany’s advanced laboratory infrastructure and its leadership in the development of diagnostic reagents and testing kits are boosting the adoption of Achlorhydria treatment solutions. In addition, public awareness campaigns about digestive health and nutrition deficiencies are fostering demand across hospitals and specialty clinics.

Asia-Pacific Achlorhydria Treatment Market Insight

The Asia-Pacific achlorhydria treatment market is projected to be the fastest-growing region during the forecast period, propelled by rising cases of malnutrition, expanding healthcare access, and increasing awareness regarding gastric acid deficiency disorders. Countries such as China, India, and Japan are witnessing a growing patient population due to poor dietary patterns and chronic use of acid-suppressing drugs. Government healthcare initiatives and investments in early diagnostic programs are further promoting market growth. Rapid improvements in medical infrastructure, coupled with the availability of affordable diagnostic testing kits and generic drugs, are enhancing accessibility and adoption across emerging economies.

Japan Achlorhydria Treatment Market Insight

The Japan achlorhydria treatment market is gaining momentum due to the country’s technologically advanced healthcare system and emphasis on preventive medicine. The aging population, which is more susceptible to gastric mucosal atrophy, is a key contributor to demand. In addition, Japan’s strong biotechnology and diagnostic sector is developing innovative, non-invasive testing methods for gastric function assessment.

China Achlorhydria Treatment Market Insight

The China achlorhydria treatment market accounted for the largest revenue share within Asia-Pacific in 2024, supported by rising healthcare expenditure, rapid urbanization, and increased focus on early diagnosis of gastric disorders. The government’s emphasis on rare and chronic disease management, coupled with the availability of locally manufactured, cost-effective diagnostic tools, is expanding market penetration. Furthermore, partnerships between global and domestic pharmaceutical players are fostering access to advanced Achlorhydria therapies.

Achlorhydria Treatment Market Share

The Achlorhydria Treatment industry is primarily led by well-established companies, including:

• AbbVie Inc. (U.S.)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• AstraZeneca plc (U.K.)
• Novartis AG (Switzerland)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• Merck & Co., Inc. (U.S.)
• Eisai Co., Ltd. (Japan)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Cipla Ltd. (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Torrent Pharmaceuticals Ltd. (India)
• Abbott (U.S.)

Latest Developments in Global Achlorhydria Treatment Market

• In February 2024, a comprehensive review published in Nutrients emphasized therapeutic advancements for Autoimmune Atrophic Gastritis (AAG), a primary cause of achlorhydria. The study highlighted the growing clinical acceptance of acid replacement therapies such as betaine hydrochloride to restore digestive function and reduce complications associated with acid deficiency. This review encouraged further clinical trials focused on targeted pharmacological interventions to manage achlorhydria more effectively
• In August 2023, researchers in Gastroenterology & Hepatology presented findings indicating the absence of standardized immunosuppressive or regenerative therapies for the gastric parietal cell destruction responsible for achlorhydria. The study called for new drug research targeting gastric mucosal regeneration and immune modulation, marking a key research direction in digestive health therapeutics
• In June 2023, healthcare experts observed a notable rise in diagnostic awareness for achlorhydria and related conditions like hypochlorhydria. The adoption of diagnostic tools such as serum gastrin tests, gastric pH monitoring, and intrinsic factor antibody testing increased significantly, particularly in North America and Europe. This development is expanding the diagnostic segment of the market and encouraging early-stage intervention
• In November 2022, clinical scientists reported progress in developing advanced formulations of hydrochloric acid and enzyme supplements aimed at treating chronic acid deficiency. These formulations demonstrated improved absorption and tolerance rates in pilot studies, paving the way for future therapeutic options for achlorhydria management

SKU-63680